Immunotherapeutic vaccines developer Imcyse is set to initiate the Phase Ib clinical trial of Imotopes for the treatment of insulin-dependent (type 1) diabetes, following the authorisation from the regulatory authorities of Belgium and the UK.

Developed using the firm’s Imotopes technology, which blocks the immune cells that destroy the insulin-producing beta cells in the pancreas, Imotopes are specific modified peptides that activate a new type of T-cell called cytolytic T-cells.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The use of a specific Imotope is claimed to block the altered immune response involved in the destruction of the pancreas.

The Phase Ib trial is to be performed at 18 clinical sites across Belgium, France, Germany, the UK and Denmark, and will enrol patients who were diagnosed within six months before their recruitment.

"The start of the clinical trial for this product is a major milestone for Imcyse and a recognition by the regulatory authorities of the quality of the data generated by our team."

Imcyse CEO Pierre Vandepapelière said: “The start of the clinical trial for this product is a major milestone for Imcyse and a recognition by the regulatory authorities of the quality of the data generated by our team.

“Imcyse aims to develop treatments to halt the disease process when the first signs of autoimmune disease emerge, thereby preventing the development of the disease and the onset of complications.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the data from preclinical studies, a prolonged effect was observed after a few subcutaneous injections of Imotopes.

The trial is being conducted in partnership with the French National Institute of Health and Medical Research (INSERM) and is under the EXALT programme supported by the European Union’s Seventh Framework Programme for Research and Technological Development.